Abstract
Ayel Luis R. Batac, Kaitlyn A. Merrill, Nicole Askin, Michael A. Golding, Elissa Michele Abrams, Philippe Bégin, Moshe Ben‐Shoshan, Erika Ladouceur, Leslie E. Roos, Vladan Protudjer, Jennifer L. P. Protudjer
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
openalex
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Maternal psychological distress a mental health service use during the COVID-19 pandemic
10.1016/j.jad.2020.07.081 · 2020
High anxiety and health-related quality of life in families with children with food allergy during coronavirus disease 2019
10.1016/j.anai.2020.09.010 · 2021
COVID-19-related media consumption and parental mental health
10.1037/cbs0000280 · 2021
eHealth literacy: essential skills for consumer health in a networked world
10.2196/jmir.8.2.e9 · 2006
Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases
10.1080/21645515.2020.1780846 · 2020
Vaccine hesitancy: the next challenge in the fight against COVID-19
10.1007/s10654-020-00671-y · 2020
10.15585/mmwr.mm7004e1
10.15585/mmwr.mm7004e1
The safety profile of COVID-19 vaccinations in the United States
10.1016/j.ajic.2021.10.015 · 2022
10.1016/j.jaip.2021.04.025
10.1016/j.jaip.2021.04.025
Experience of the first 1127 COVID-19 vaccine allergy safety patients in Hong Kong - clinical outcomes, barriers to vaccination, and urgency for reform
10.1016/j.waojou.2021.100622 · 2022
Vaccine hesitancy and (fake) news: quasi-experimental evidence from Italy
10.1002/hec.3937 · 2019
Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions: early report
10.1016/j.anai.2021.03.012 · 2021
Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol?
10.1111/all.14711 · 2021
Experience with polyethylene glycol allergy-guided risk management for COVID-19 vaccine anaphylaxis
10.1111/all.15183 · 2022
Utility and futility of skin testing to address concerns surrounding messenger RNA coronavirus disease 2019 vaccine reactions
10.1016/j.anai.2021.11.006 · 2022
Second-dose COVID-19 vaccines are well tolerated in patients with allergic reactions to the first dose - a single center experience
10.1016/j.waojou.2022.100654 · 2022
Management of suspected and confirmed COVID-19 (SARS-CoV-2) vaccine hypersensitivity
10.1111/all.15414 · 2022
Successful mRNA COVID-19 vaccination in a patient with a history of severe polyethylene glycol anaphylaxis
10.1186/s13223-022-00698-8 · 2022
Scoping studies: towards a methodological framework
10.1080/1364557032000119616 · 2005
PRISMA Extension for scoping reviews (PRISMA-ScR): checklist and explanation
10.7326/m18-0850 · 2018
Vaccine confidence amongst those living with allergy during the COVID pandemic (ACCORD): a scoping review protocol
10.1186/s13223-022-00723-w · 2022
PRESS peer review of electronic search strategies: 2015 guideline statement
10.1016/j.jclinepi.2016.01.021 · 2016
Acute allergic reactions to mRNA COVID-19 vaccines
10.1001/jama.2021.3976 · 2021
Surveillance for adverse events after COVID-19 mRNA vaccination
10.1001/jama.2021.15072 · 2021
Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system
10.1001/jamanetworkopen.2021.25524 · 2021
Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don’t give up on the second dose!
10.1111/all.14958 · 2021
Allergic reactions to coronavirus disease 2019 vaccines and addressing vaccine hesitancy: Northwell Health experience
10.1016/j.anai.2021.10.019 · 2022
Pfizer/BioNtech BNT162b2: adverse events and insights from an Australian mass vaccination clinic for COVID-19
10.1111/imj.15623 · 2022
Adverse reactions and safety profile of the mRNA COVID-19 vaccines among Asian military personnel
10.47102/annals-acadmedsg.2021345 · 2021
Adverse reactions following COVID-19 vaccination: an Ecuadorian experience
10.1016/j.amsu.2021.103044 · 2021
Allergic symptoms after mRNA COVID-19 vaccination and risk of incomplete vaccination
10.1016/j.jaip.2021.05.031 · 2021
COVID-19 vaccination reactogenicity in persons with multiple sclerosis
10.1212/nxi.0000000000001104 · 2022
Three doses of COVID-19 mRNA vaccination are safe based on adverse events reported in electronic health records
2021
An mRNA vaccine against SARS-CoV-2 - preliminary report
10.1056/nejmoa2022483 · 2020
Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
10.1056/nejmoa2034577 · 2020
Efficacy and safety of the mRNA-1273 SARS-CoV-2 caccine
10.1056/nejmoa2035389 · 2021
Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico
10.1056/nejmoa2116185 · 2022
Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine
10.1056/nejmoa2105290 · 2021
Efficacy and safety of a recombinant plant-based adjuvanted Covid-19 vaccine
10.1056/nejmoa2201300 · 2022
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
10.1016/s0140-6736(21)01429-x · 2021
Primary care provider-reported prevalence of vaccine and polyethylene glycol allergy in Canada
10.1016/j.anai.2021.05.011 · doi-reference
Under-reporting of adverse drug reactions: a systematic review
10.2165/00002018-200629050-00003 · doi-reference
10.7249/rra112-7
10.7249/rra112-7 · doi-reference
The role of the affect and availability heuristics in risk communication
10.1111/j.1539-6924.2006.00773.x · doi-reference
After years of media coverage, can one more video report trigger heuristic judgments? A national study of American terrorism risk perceptions
10.1080/19434471003768826 · doi-reference
COVID-19 vaccination in patients with reported allergic reactions: updated evidence and suggested approach
10.1016/j.jaip.2021.03.053 · doi-reference
Covid-19: people with history of significant allergic reactions should not receive Pfizer vaccine, says regulator
10.1136/bmj.m4780 · doi-reference
Risk of anaphylaxis after vaccination in children and adults
10.1016/j.jaci.2015.07.048 · doi-reference
Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine
10.1016/j.vaccine.2013.10.033 · doi-reference
The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach
10.1016/j.jaip.2021.06.006 · doi-reference
COVID-19 vaccination in Chinese children: a cross-sectional study on the cognition, psychological anxiety state and the willingness toward vaccination
10.1080/21645515.2021.1949950 · doi-reference
Willingness to receive a booster dose of inactivated coronavirus disease 2019 vaccine in Taizhou, China
10.1080/14760584.2022.2016401 · doi-reference
First-dose coronavirus 2019 vaccination coverage among the residents of long-term care facilities in France
10.1159/000517793 · doi-reference
Healthcare provider attitudes toward the newly developed COVID-19 vaccine: cross-sectional study
10.3390/nursrep11010018 · doi-reference
Public willingness and determinants of COVID-19 vaccination at the initial stage of mass vaccination in China
10.3390/vaccines9101172 · doi-reference
The perception and attitudes toward COVID-19 vaccines: a cross-sectional study in Poland
10.3390/vaccines9040382 · doi-reference
Analyzing the attitude of Indian citizens towards COVID-19 vaccine - a text analytics study
10.1016/j.dsx.2021.02.031 · doi-reference
Assessment of COVID-19 vaccines acceptance in the Lebanese population: a national cross-sectional study
10.1186/s40545-021-00403-x · doi-reference
The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: early data from a single-institute survey
10.1016/j.ejca.2021.05.006 · doi-reference
Survey of adult and paediatric rheumatology patients suggests information about COVID-19 vaccination will aid uptake
10.1093/rheumatology/keab169 · doi-reference
Acceptance and attitude toward COVID-19 vaccination among the public in Saudi Arabia: a cross-sectional study
10.5005/jp-journals-10024-3114 · doi-reference
Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose
10.1001/jamainternmed.2021.3779 · doi-reference
Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19
10.1016/j.jaip.2021.07.012 · doi-reference
Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine
10.1111/cea.13874 · doi-reference
An academic hospital experience screening mRNA COVID-19 vaccine risk using patient allergy history
10.1016/j.jaip.2021.07.010 · doi-reference
The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID-19 vaccine
10.1111/all.15148 · doi-reference
Local and systemic adverse effects of CoronaVac vaccine in risk groups: prospective, cross-sectional study
10.5336/dermato.2021-85208 · doi-reference
Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health-care system experience
10.2500/aap.2021.42.210069 · doi-reference
Safety of COVID-19 vaccines
10.1002/jmv.27214 · doi-reference
Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): a prospective cohort study with intensive monitoring
10.1016/j.vaccine.2022.01.062 · doi-reference
Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study
10.1016/j.dsx.2021.102207 · doi-reference
Analysis of COVID-19 vaccine type and adverse effects following vaccination
10.1001/jamanetworkopen.2021.40364 · doi-reference
Disproportionality analysis of anaphylactic reactions after vaccination with messenger RNA coronavirus disease 2019 vaccines in the United States
10.1016/j.anai.2021.04.004 · doi-reference
The polysorbate containing AstraZeneca COVID-19 vaccine is tolerated by polyethylene glycol (PEG) allergic patients
10.1111/cea.14064 · doi-reference
Specialist confirmed allergic reactions to COVID-19 mRNA vaccines at a mass vaccination site
10.1016/j.vaccine.2021.06.061 · doi-reference
Adverse events report of inactivated COVID-19 vaccine from 4040 healthcare workers
10.1080/00325481.2021.1999708 · doi-reference
Delayed systemic urticarial reactions following mRNA COVID-19 vaccination
10.2500/aap.2022.43.210101 · doi-reference
Skin adverse reactions to novel messenger RNA coronavirus vaccination: a case series
10.3390/diseases9030058 · doi-reference
Prevalence of allergic reactions after Pfizer-BioNTech COVID-19 vaccination among adults with high allergy risk
10.1001/jamanetworkopen.2021.22255 · doi-reference
Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine
10.1016/j.vaccine.2021.09.048 · doi-reference